Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acegenix-SP
- Development stage
- Unknown
- Lead developer
- Nilegenix
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Acegenix-SP is a fixed-dose combination (FDC) pharmaceutical product developed and marketed by Nilegenix, a generic pharmaceutical company based in India. It typically contains three active ingredients: aceclofenac, paracetamol (acetaminophen), and serratiopeptidase. Aceclofenac is a non-steroidal anti-inflammatory drug (NSAID) that reduces pain and inflammation by inhibiting cyclooxygenase (COX) enzymes. Paracetamol serves as an analgesic and antipyretic agent. Serratiopeptidase is a proteolytic enzyme that helps reduce swelling and edema by breaking down abnormal proteins at the site of inflammation and promoting tissue repair. This combination is primarily indicated for the management of pain, swelling, and inflammation associated with conditions such as post-surgical recovery, traumatic injuries, and musculoskeletal disorders.
- Brand names
- Acegenix-SP
- Other names
- Aceclofenac + Paracetamol + Serratiopeptidase
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on Acegenix-SP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Acegenix-SP.